Propylhexedrine
Viewing r1 — May 12, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Propylhexedrine — Benzedrex — is a synthetic stimulant of the substituted amphetamine class. Derived from methamphetamine through hydrogenation of the phenyl ring, it trades CNS potency for peripheral sympathomimetic activity. Propylhexedrine is a norepinephrine–dopamine releasing agent, producing its effects by reversing monoamine transporters to flood synapses with stimulatory neurotransmitters.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Synthesized by Glenn E. Ullyot and patented in 1948, propylhexedrine entered the market as Benzedrex in 1949 — a replacement for amphetamine sulfate inhalers following widespread amphetamine abuse.[2][3] The WHO reviewed the compound in 1986 and concluded it carries low abuse potential relative to amphetamine.[4] It remains available without prescription in the United States, where poison control cases have risen sharply since 2011.[5]
Subjective effects include stimulation, euphoria, wakefulness, and appetite suppression. The experience is defined by a disproportion between cardiovascular intensity and cognitive reward — pronounced palpitations, sweating, and vasoconstriction accompany a modest, rough-edged stimulant high that lacks the refinement of amphetamine.[4] Paranoia, psychosis, and uncomfortable peripheral body load are characteristic unsought effects.
Propylhexedrine produces rapid tolerance and documented dependence,[2] with cardiovascular toxicity — pulmonary hypertension and sudden death — as the primary lethal risk.[6] Both oral and intravenous abuse produce pulmonary vascular disease; the margin between a stimulant effect and organ damage is poorly defined. No controlled human study has been published — the entire evidence base rests on case reports and adverse event surveillance.[5]
History[edit]
Discovery
Propylhexedrine was synthesized by Glenn E. Ullyot at Smith, Kline & French Laboratories and patented in 1948. The compound was created by hydrogenating methamphetamine's phenyl ring into a saturated cyclohexyl group — deliberately reducing CNS potency while preserving nasal decongestant activity.[1] It entered national commerce on August 4, 1949 as Benzedrex, replacing amphetamine sulfate in SK&F's over-the-counter inhaler after widespread amphetamine abuse, psychosis, and habituation.[3][2]
Clinical and cultural significance
Beyond nasal decongestion, propylhexedrine was marketed as an appetite suppressant in some regions, and in Europe it was incorporated into barbexaclone — a co-crystal with phenobarbital used as an anticonvulsant.[7] Intravenous abuse emerged as a serious problem in the 1970s and 1980s, with 15 propylhexedrine-related deaths documented in Dallas County alone, 12 from IV use.[6] The WHO Expert Committee on Drug Dependence reviewed the compound in 1986, concluding it carried low abuse potential relative to amphetamine and recommending against international scheduling.[4]
Modern resurgence
After briefly being placed on US Schedule V in 1988 and removed in 1991, propylhexedrine experienced a documented abuse resurgence beginning around 2011. Annual poison control cases rose from 11 in 2011 to 74 in 2019, driven by low retail price and online extraction guides.[5][8] Fernandez and Francis published the first case of propylhexedrine dependence in 2012, calling the compound "a vintage drug of abuse, rediscovered".[2]
The Benzedrex trademark was registered by Smith, Kline & French in 1944 — five years before the product launched — deliberately echoing their earlier Benzedrine brand to ease the consumer transition from the amphetamine inhaler to its safer replacement.[2] The compound occupies a peculiar niche in drug culture: an amphetamine structural analog sold openly at pharmacies and gas stations, sought primarily by users without access to preferred stimulants. Community discussions describe the experience as a "dirty" stimulant high, and the compound's reputation for disproportionate cardiovascular adverse effects relative to its modest euphoria has earned it low status among stimulant users.[4]
Chemistry[edit]
Structural class
Propylhexedrine belongs to the substituted amphetamine family within the broader phenethylamine class. Its defining structural feature is a saturated cyclohexyl ring in place of the aromatic phenyl ring found in amphetamine and methamphetamine — a modification achieved through catalytic hydrogenation.[1] This single change eliminates ring aromaticity, substantially reducing the compound's ability to cross the blood–brain barrier and lowering CNS potency while preserving peripheral sympathomimetic effects. The N-methyl group on the amine nitrogen mirrors methamphetamine, from which propylhexedrine is directly derived.
Molecular properties
| Molecular formula | C₁₀H₂₁N |
| Molecular weight | 155.28 g/mol |
The molecule consists of a cyclohexyl ring connected through a two-carbon chain to a secondary amine bearing an N-methyl group.[1] Freebase propylhexedrine is a volatile, oily liquid at room temperature with a characteristic amine odor — this is the form saturating the cotton rod inside Benzedrex inhalers. The hydrochloride salt is a water-soluble crystalline solid.
Stereochemistry
Propylhexedrine contains one chirality center at the alpha-carbon. Commercial Benzedrex inhalers contain the racemic mixture (both S- and R-enantiomers). The S-isomer (levopropylhexedrine) is reported as the more biologically active form,[1] though no published study provides a quantitative comparison between the two enantiomers.
Structure–activity relationships
The cyclohexyl-for-phenyl substitution is the critical SAR feature. Aromatic rings confer planarity and electron density that facilitate blood–brain barrier penetration; the saturated cyclohexyl ring lacks both properties, resulting in reduced CNS access.[9] This explains why propylhexedrine retains strong peripheral alpha-adrenergic activity for nasal decongestion while producing weaker central stimulation than methamphetamine.
Pharmacology[edit]
Mechanism of action
Propylhexedrine operates through two distinct mechanisms depending on dose and route.[4][1]
At therapeutic inhaler doses, it acts as a direct alpha-adrenergic agonist, constricting blood vessels in the nasal mucosa to relieve congestion. Systemic absorption is minimal and no central nervous system effects occur.[4]
At oral abuse doses (60–250+ mg), the pharmacology shifts fundamentally. Propylhexedrine reverses the norepinephrine and dopamine transporters (NET and DAT), forcing stored monoamines out of nerve terminals and into the synapse.[1] Secondary actions at TAAR1 and VMAT2 amplify this release by increasing the pool of monoamines available for reverse transport.
Some serotonin release also occurs, though norepinephrine and dopamine are considered the primary effectors.[1][8] No peer-reviewed study has published quantitative binding data for propylhexedrine at any molecular target.
Pharmacokinetics
The half-life is approximately 4 ± 1.5 hours in humans, though this estimate derives from secondary sources rather than a primary published pharmacokinetic trial.[1] Urinary pH significantly affects clearance: acidic urine accelerates elimination, while alkaline urine prolongs the half-life.
Animal data provide the only controlled pharmacokinetic parameters. In mice, oral bioavailability was approximately 37%, with rapid blood–brain barrier penetration and high tissue accumulation in the lungs, kidneys, and liver.[10]
Propylhexedrine is metabolized through multiple pathways including N-demethylation, N-oxidation, dehydrogenation, and ring hydroxylation.[1] The specific liver enzymes responsible have not been identified.citation needed Excretion is renal, with no published human data on the fraction excreted unchanged.
Neuroscience[edit]
Where it acts
As a dopamine and norepinephrine releasing agent, propylhexedrine increases dopamine concentrations in the brain's reward circuit — the mesolimbic pathway from ventral tegmental area to nucleus accumbens — producing the modest euphoria and reinforcement reported by users. The magnitude of this dopamine release is likely lower than amphetamine, consistent with the WHO assessment of low abuse potential[4] and partial substitution in animal drug discrimination tests.[11]
Simultaneous norepinephrine release through both central and peripheral pathways activates the sympathetic nervous system, explaining the pronounced cardiovascular effects — elevated heart rate, blood pressure, and vascular spasm — that are disproportionate to the compound's relatively modest subjective stimulation.
Why it matters
The incentive salience framework — the distinction between wanting a drug and liking its effects — is particularly relevant to propylhexedrine. The compound produces modest liking (euphoria weaker than amphetamine) but may generate disproportionate wanting through dopaminergic sensitization with repeated use.
The first published case of dependence described compulsive use despite awareness of harms,[2] consistent with wanting-liking dissociation. Simultaneously, tolerance to euphoria develops through downregulation, creating a dual process — escalating craving alongside diminishing reward — that characterizes stimulant addiction trajectories.
Brainstem dysfunction documented in IV users — including persistent eye movement disorders and hemitongue paralysis within seconds of injection[3] — remains unexplained. Whether this reflects direct neurotoxicity, blood vessel spasm in brainstem vasculature, or embolic damage from injected particulate matter is unresolved.
Subjective Effects[edit]
At oral abuse doses, propylhexedrine produces an experience defined by the imbalance between its peripheral and central effects. Cardiovascular activation — pounding heart, sweating, vasoconstriction, and temperature dysregulation — arrives with intensity that outweighs the cognitive reward accompanying it. At lower abuse doses, mild stimulation and mood lift predominate; as doses increase, the somatic load escalates faster than euphoria, producing a ceiling on subjective pleasure while cardiovascular strain continues to mount.
Compared to amphetamine, propylhexedrine delivers a rougher, more body-heavy stimulant experience with less cognitive enhancement and focus.[4] Users familiar with amphetamine-class stimulants consistently describe the character as less clean — more peripheral activation relative to the mental clarity and drive they associate with traditional stimulants.
Effect Grid
Clear stimulant effects manifest: sustained wakefulness, definite appetite suppression, and mild-to-moderate euphoria. Thought acceleration and focus enhancement are reported. Mood is elevated with increased motivation and sociability.
Physical effects become clinically relevant — noticeable tachycardia, vasoconstriction, temperature dysregulation, and sweating. Bruxism may emerge. Pupil dilation is apparent. Dehydration sensation prompts increased fluid intake. Increased urination is common.
This range (60–120 mg) represents roughly one-quarter to one-half of a Benzedrex inhaler. Sleep is disrupted for 4–6+ hours. Cardiovascular strain warrants caution in individuals with any cardiac risk factors.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
External hallucinations · Shadow people
Physical fatigue · Dry mouth · Heart rate perception changes · Insomnia · Pupil dilation · Restlessness · Body high · Dehydration sensation · Excessive sweating · Muscle tension · Bruxism · Dizziness · Headache · Nasal congestion · Nausea · Respiratory stimulation · Temperature dysregulation · Trembling · Sexual arousal enhancement · Vomiting · Tactile hallucination
Insomnia · Pupil dilation · Restlessness · Body high · Dehydration sensation · Excessive sweating · Muscle tension · Bruxism · Dizziness · Headache · Nasal congestion · Nausea · Respiratory stimulation · Trembling · Sexual arousal enhancement · Vomiting · Tactile hallucination
Cognitive dysphoria · Cognitive euphoria · Focus enhancement · Motivation enhancement · Information processing enhancement · Analysis enhancement · Memory enhancement · Cognitive impairment · Confusion · Delusions of sobriety · Thought disorganization · Thought loops · Delirium · Delusions
Motivation enhancement · Information processing enhancement · Analysis enhancement · Memory enhancement · Cognitive impairment · Confusion · Thought disorganization · Thought loops · Delirium · Delusions
Irritability · Dysphoria · Emotional lability · Mania
Ego inflation · Sociability suppression · Social disconnection · Flow state · Depersonalization · Derealization · Cognitive disconnection
Depersonalization · Derealization · Cognitive disconnection
Timeline
Initial peripheral stimulation emerges — subtle heart rate increase and mild alertness. Effects are sub-threshold for most cognitive or perceptual changes.
Progressive stimulation with cardiovascular activation becoming apparent. Tachycardia, mild vasoconstriction, and appetite suppression develop. Mood begins to elevate.
Full stimulant effects — maximum euphoria, wakefulness, and cardiovascular strain. Sweating, bruxism, and temperature dysregulation are most pronounced. Focus enhancement and thought acceleration peak.
Gradual decline in stimulation. Cardiovascular effects may persist longer than subjective stimulation. Fatigue, irritability, and depressed mood begin to emerge.
Residual fatigue, possible depressed mood, and appetite return. Cardiovascular parameters normalizing. Sleep may remain difficult for several hours.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- High
- Withdrawal
- Mild
- Tolerance buildup
- rapid
- Tolerance reset
- 10.5 days
- Physical
- Low
- Psychological
- Moderate
- Compulsive redosing
- Moderate
- Dose escalation
- Moderate
- Cross-tol.
- amphetamine · methamphetamine · methylphenidate
Toxicity
Acute toxicity
No lethal dose has been established in humans and no formal therapeutic index exists. FDA surveillance (2000–2019) identified 460 poison control cases involving propylhexedrine abuse, 21 life-threatening outcomes, and 13 ICU admissions. Among serious adverse event reports, 9 deaths were documented — 6 involving polydrug use, 1 attributed to propylhexedrine alone.[5] The total medical literature documents 49 case reports and 18 deaths.[5]
Cardiovascular toxicity
Heart and blood vessel damage is the leading cause of propylhexedrine-related death. Intravenous use carries extreme risk: a case series documented 15 deaths in a single county, 12 from IV abuse, with consistent findings of lung damage, high pressure in the pulmonary arteries, and enlargement of the right side of the heart.[6]
Oral abuse also produces pulmonary vascular disease — one case documented pulmonary hypertension after 8 years of daily oral use as an appetite suppressant.[12] Inhaled propylhexedrine combined with methamphetamine produced marked pulmonary hypertension in another case.[13]
Additional documented cardiovascular complications include heart attack,[3] dangerous heart rhythms,[5][14] and severe blood pressure elevation.[15][5]
Neurological toxicity
Brainstem damage from IV abuse has been documented in 7 cases, including persistent eye movement disorders and tongue paralysis lasting months.[3] Oral misuse has produced neurological impairment with brain scan abnormalities in at least one case.[14]
Injection site complications
IV injection has caused massive neck swelling, tissue death requiring surgery, kidney failure, and fatal cardiac arrest.[16]
Psychological risks
Psychosis, paranoia, and hallucinations are documented across both IV and oral abuse routes.[3][2][5] These risks were recognized as early as 1949, when propylhexedrine replaced amphetamine sulfate — itself withdrawn partly due to psychosis reports.
No controlled data characterize the dose threshold or prevalence of propylhexedrine-induced psychosis. By analogy with amphetamine-class stimulants, risk increases with dose escalation, sleep deprivation, and repeated use.inferred
Tolerance & dependence
Tolerance develops rapidly with repeated use, consistent with all norepinephrine–dopamine releasing agents. Cross-tolerance with other dopaminergic stimulants (amphetamine, methamphetamine, methylphenidate) is expected based on shared mechanisms.
One published case of propylhexedrine dependence exists,[2] and barbexaclone dependence (propylhexedrine component) has been documented separately.[17] No formal quantitative assessment of dependence potential has been conducted.[2][4]
No specific withdrawal has been characterized for propylhexedrine. By analogy with amphetamine-class stimulants, withdrawal would be expected to involve fatigue, excessive sleep, low mood, appetite enhancement, and craving.inferred
Drug interactions
Monoamine oxidase inhibitors (MAOIs — including isocarboxazid, phenelzine, tranylcypromine, selegiline, linezolid) are an absolute contraindication. MAOIs prevent the breakdown of monoamines; when propylhexedrine forces massive release into synapses where breakdown is blocked, uncontrolled norepinephrine accumulation produces life-threatening blood pressure crisis. Serotonin syndrome may co-occur.safety citation needed
Tramadol combines additive seizure risk, cardiovascular strain, and potential serotonin toxicity. One FDA adverse event involving propylhexedrine with tramadol and other substances resulted in death.[5]safety citation needed
Kratom (mitragynine) is documented in one fatal case where propylhexedrine toxicity was ruled the cause of death and mitragynine may have contributed.[18]
Other stimulants (cocaine, amphetamine, MDMA) carry additive cardiovascular risk. MDMA combined with propylhexedrine produces synergistic cardiovascular strain and potential serotonin toxicity.
Alcohol interaction is uncharacterized. No published case reports or studies exist. Blood vessel dilation from alcohol could theoretically offset some blood pressure effects while simultaneously increasing irregular heartbeat risk.
Contraindications
Absolute:
- MAOI use within 14 days — risk of life-threatening blood pressure crisis from uncontrolled norepinephrine accumulationsafety citation needed
Relative:
- Heart disease or uncontrolled high blood pressure — propylhexedrine increases cardiac workload and blood pressure; documented association with pulmonary hypertension[6][12] and heart attack[3] makes pre-existing cardiovascular disease a significant risk amplifierinferred
- Seizure disorder — stimulant activity may lower seizure thresholdinferred
- Pregnancy — sympathomimetic vasoconstriction poses theoretical risk to fetal blood supplysafety citation needed
- Serotonergic medications — if propylhexedrine's serotonin-releasing activity is clinically significant, combinations with SSRIs, SNRIs, or other serotonergic agents could produce serotonin syndromeinferred
Harm Reduction[edit]
Forms & Identification
Propylhexedrine is encountered almost exclusively as the cotton rod inside Benzedrex nasal inhalers, each containing approximately 250 mg of freebase propylhexedrine along with menthol and lavender oil. There is no illicitly manufactured propylhexedrine market — the compound is not sold as powder, pill, or crystal by drug suppliers. Identification is straightforward since the source is always the commercial inhaler, but extraction efficiency varies with method, and the entire contents of one inhaler represent a heavy dose with disproportionate cardiovascular risk.
Guidelines
- Test cardiovascular tolerance with the lowest possible dose before considering higher amounts
- Never use the entire cotton rod contents (250 mg) as a single dose — this represents a heavy dose with disproportionate cardiovascular risk
- Stay hydrated but avoid excessive water intake, which can disrupt electrolyte balance
- Monitor heart rate if possible — persistent resting heart rate above 150 bpm warrants medical attention
- Avoid physical exertion during the experience — the cardiovascular system is already under significant strain
- Do not inject propylhexedrine under any circumstances — IV use carries extreme risk of pulmonary damage, brainstem injury, tissue death, and sudden death[6]
Set & Setting
Propylhexedrine's pronounced cardiovascular effects make physical setting important. A calm, temperature-controlled environment reduces the strain of stimulant-driven temperature dysregulation and elevated heart rate. Having a sober companion present is advisable given the risk of cardiac events and the potential for paranoia at higher doses.
Aftercare & integration. The stimulant comedown from propylhexedrine typically involves fatigue, low mood, and appetite enhancement. Prioritize sleep — the compound's 4-hour half-life means effects taper within 8–10 hours, but sleep disruption may persist longer.
Eat balanced meals, hydrate steadily, and avoid redosing to chase fading effects. Compulsive redosing urges are reported and escalate cardiovascular risk with each additional dose. Allow at least 1–2 weeks between uses to permit partial tolerance reset.
Recovery & Support
Propylhexedrine dependence is rare but documented.[2] Compulsive use patterns — particularly daily extraction from multiple inhalers — should be treated as stimulant use disorder. Standard stimulant addiction resources apply: SAMHSA National Helpline (1-800-662-4357), local addiction services, and support communities familiar with stimulant dependence.
Anyone experiencing regular cravings, dose escalation, or continued use despite cardiovascular symptoms should seek professional assessment. There is no specific medical detox protocol for propylhexedrine; treatment follows general stimulant withdrawal management.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: chest pain, irregular heartbeat, difficulty breathing, seizure, loss of consciousness, or extreme confusion following propylhexedrine use are medical emergencies. Paranoia and agitation alone are uncomfortable but not immediately life-threatening — chest pain and breathing difficulty are the critical red flags.
Immediate steps:
- Call emergency services immediately if chest pain, seizure, or loss of consciousness occurs
- Keep the person calm and still — physical exertion worsens cardiovascular strain
- Move to a cool environment if overheating is evident
- If unconscious but breathing, place in the recovery position
- Do not induce vomiting
- Do not restrain an agitated person unless they pose immediate danger to themselves or others
What to tell the dispatcher: Name the substance (propylhexedrine / Benzedrex), approximate amount consumed, time of ingestion, and current symptoms. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
Propylhexedrine occupies an unusual regulatory position: an amphetamine structural analog available without prescription in the United States despite documented fatal abuse. International scheduling was briefly imposed in 1988 and reversed in 1991. The compound is not currently controlled under the Convention on Psychotropic Substances.[4][19]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | OTC (unscheduled federally) | Removed from CSA Schedule V in 1991. State-level restrictions in Alaska, Arizona, Florida, Georgia, Idaho, Kansas, and Rhode Island. FDA Drug Safety Communication issued 2021.[15] |
| United Kingdom | Unscheduled | Removed from Misuse of Drugs Act 1971 via 1995 Modification Order.[19] |
| Australia | Schedule 4 (prescription only) | Listed in Poisons Standard.[19] |
| Canada | Unscheduled | Previously Schedule V under Controlled Drugs and Substances Act; removed 2022.[19] |
| Germany | Prescription only | Requires medical prescription.[19] |
| Brazil | Class B1 (controlled) | Controlled substance classification.[19] |
The 2021 FDA Drug Safety Communication warned of serious harm from abuse and misuse, citing deaths, pulmonary hypertension, and cardiovascular events, but stopped short of recommending rescheduling or prescription-only status.[5]
references
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]